Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial
The University of Texas MD Anderson Cancer Center · Rigshospitalet · +19 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
511
total citations
- FWCI
- 62.07
- Percentile
- 100%
- References
- 37
Citations per year
Authors
19Topics & keywords
Topics
Keywords
- Trametinib
- Dabrafenib
- Biliary tract cancer
- Medicine
- Open label
- Internal medicine
- Oncology
- Biliary tract
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.
Funding
- GGlaxoSmithKline
- NNovartis
- CPCancer Prevention and Research Institute of TexasAwards: grant RP110584, RP110584
- NCNorth Carolina GlaxoSmithKline Foundation
- NPNovartis Pharmaceuticals Corporation
- NINational Institutes of HealthAwards: CA016672, grant CA016672
- CFCenter for Clinical and Translational Sciences, University of Texas Health Science Center at Houston
- NCNational Cancer InstituteAwards: 1R01CA242845-01A1, grant 1R01CA242845-01A1
- NCNational Center for Advancing Translational SciencesAwards: UL1 TR000371, grant UL1 TR000371